Literature DB >> 17634390

Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.

Kazuho Sakamoto1, Takashi Honda, Sachihiko Yokoya, Satoshi Waguri, Junko Kimura.   

Abstract

Three-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors, known as statins, induce skeletal muscle injury including myalgia, myositis, and rhabdomyolysis. The mechanism of this myotoxicity remains unknown. This study examined the effect of statins on single skeletal myofibers enzymatically isolated from the rat flexor digitorum brevis muscles. Fluvastatin and pravastatin induced the formation of numerous vacuoles in the myofibers after 72 h of treatment. This effect progressed in a time- and concentration-dependent manner and, consequently, cell death occurred after 120 h. Electron micrographs revealed craters along the sarcolemma and swelling of the sarcoplasmic reticula and mitochondria, in addition to intracellular vacuoles. When caffeine was added after 72 h of fluvastatin treatment, contractile shortening of statin-treated myofibers was significantly attenuated and blebs formed on the surface of the myofibers. The coapplication of geranylgeranylpyrophosphate (GGPP) with fluvastatin prevented the morphological changes, while that of farnesylpyrophosphate (FPP) was ineffective. Furthermore, perillyl alcohol, an inhibitor of Rab geranylgeranyl transferase and geranylgeranyl transferase-I (GGTase-I), mimicked the effect of statins, while a specific GGTase-I inhibitor (GGTI-298) or a farnesyl transferase inhibitor (FTI-277) failed to do so. These results suggest that the inactivation of Rab GTPase, which involved in intracellular membrane transport, is a crucial factor in statin-induced-morphological abnormality in skeletal muscle fibers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634390     DOI: 10.1096/fj.07-8713com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  15 in total

1.  A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells.

Authors:  Komal M Sane; Michelle Mynderse; Daniel T Lalonde; Ivory S Dean; Jonathan W Wojtkowiak; Farid Fouad; Richard F Borch; John J Reiners; Richard A Gibbs; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

2.  Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.

Authors:  K Sakamoto; H Mikami; J Kimura
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

3.  A small-molecule screening strategy to identify suppressors of statin myopathy.

Authors:  Bridget K Wagner; Tamara J Gilbert; Jun-ichi Hanai; Shintaro Imamura; Nicole E Bodycombe; Robin S Bon; Herbert Waldmann; Paul A Clemons; Vikas P Sukhatme; Vamsi K Mootha
Journal:  ACS Chem Biol       Date:  2011-07-15       Impact factor: 5.100

Review 4.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

5.  Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression.

Authors:  Bingjing Wang; Zhaohui Yang; Becky K Brisson; Huisheng Feng; Zhiqian Zhang; Ellen M Welch; Stuart W Peltz; Elisabeth R Barton; Robert H Brown; H Lee Sweeney
Journal:  J Appl Physiol (1985)       Date:  2010-06-17

6.  Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect.

Authors:  Peirang Cao; Jun-Ichi Hanai; Preeti Tanksale; Shintaro Imamura; Vikas P Sukhatme; Stewart H Lecker
Journal:  FASEB J       Date:  2009-04-30       Impact factor: 5.191

7.  Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy.

Authors:  Joanne E Mallinson; Dumitru Constantin-Teodosiu; James Sidaway; F Russell Westwood; Paul L Greenhaff
Journal:  J Physiol       Date:  2008-11-10       Impact factor: 5.182

8.  Simvastatin inhibits glucose metabolism and legumain activity in human myotubes.

Authors:  Robert Smith; Rigmor Solberg; Linn Løkken Jacobsen; Anette Larsen Voreland; Arild Christian Rustan; G Hege Thoresen; Harald Thidemann Johansen
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

9.  Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure.

Authors:  Kazuya Kato; Kazuhiko Onodera; Yoshiaki Iwasaki; Minoru Matsuda; Takako Kawakami; Mineko Higuchi; Kimitaka Kato; Yurina Kato; Masahiko Taniguchi; Hiroyuki Furukawa
Journal:  Int J Surg Case Rep       Date:  2015-01-28

10.  Pathogenic mechanisms and the prospect of gene therapy for choroideremia.

Authors:  Ioannis S Dimopoulos; Stephanie Chan; Robert E MacLaren; Ian M MacDonald
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-01       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.